A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

Inclusion Criteria: Part A 1. Males or females, between 18 and 45 years of age, inclusive, at screening. 2. Body weight ≥ 50 kg for males and body weight ≥ 45 kg for females. 18≤body mass index (BMI)\<28 kg/m2 for nonobese subjects and 28≤BMI≤45 kg/m2 for obese subjects. Part B 1. Males or females, between 18 and 65 years of age, inclusive, at screening. 2. 24 kg/m2≤BMI≤35 kg/m2. 3. Subjects diagnosed with T2DM, newly diagnosed subjects at screening, or treated with diet and exercise alone within 3 months before screening and still have poor blood glucose control, or treated with a stable dose of metformin for ≥ 3 months before screening. 4. 7.0%≤ HbA1c ≤10.5% at screening. Exclusion Criteria: Part A 1. Smoked more than 5 cigarettes per day within 3 months before the study. 2. Immunization with a live attenuated vaccine or coronavirus vaccination within 1 month prior to screening or planned vaccination during the course of the study. 3. Positive alcohol breath test result or positive urine drug screen. 4. Blood donation (\> 300 mL) or massive blood loss (\> 400 mL) within 3 months before screening. Part B 1. Have type 1 diabetes mellitus. 2. Have had ≥1 episode of severe hypoglycemia within 6 months before screening, or history of recurrent hypoglycemia (history of hypoglycemia more than 3 times in 3 months). 3. Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level \>5 times the upper limit of the reference range at screening. 4. Have serum calcitonin ≥20 ng/L at screening. 5. Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2; or have hereditary diseases that can easily induce MTC. 6. Fasted triglycerides \> 5.7 mmol/L at screening. If the patient is on lipid-lowering therapies, doses must be stable for 30 days prior to screening.